Table 4.

Best treatment response assessed by RECIST 1.1

Categories	CR (n, %)	PR (n, %)	SD (n, %)	PD (n, %)	ORR (n, %)	P
Whole Cohort	1 (6.7)	3 (20.0)	3 (20.0)	8 (53.3)	4 (26.7)
Tumor origin						0.462
Cutaneous origin	1 (11.1)	2 (22.2)	2 (22.2)	4 (44.4)	3 (33.3)
Uveal origin	0 (0.0)	1 (16.7)	1 (16.7)	4 (66.7)	1 (16.7)
Intrahepatic tumor size (cm)						0.154
< 5	1 (10.0)	3 (30.0)	0 (0.0)	6 (60.0)	4 (40.0)
≥ 5	0 (0.0)	0 (0.0)	3 (60.0)	2 (40.0)	0 (0.0)
Previous Pembrolizumab i.v						0.538
No	0 (0.0)	2 (22.2)	2 (22.2)	5 (55.6)	2 (22.2)
Yes	1 (16.7)	1 (0.0)	1 (0.0)	3 (66.7)	2 (33.3)

ORR, overall response rate. P value was calculated by comparing ORR rates between subgroups using two sided Fisher-exact Chi-square test